Back to search

Article

Elexacaftor/Tezacaftor/Ivacaftor and Neuropsychiatric Symptoms: Nonclinical and Clinical Studies

2025-10-20

Abstract excerpt

<h4>Rationale</h4> Cystic fibrosis (CF) is a chronic, life-limiting genetic disease. CFTR modulators such as elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) have significantly improved clinical outcomes and quality of life for many people with CF. While most individuals report no change or improvement in neuropsychiatric symptoms with ELX/TEZ/IVA, a minority experience new or worsening symptoms. <h4>Objectives...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
640f78f9-3281-5bf7-b0b9-68c8819ef327
DOI
10.1101/2025.10.16.25338186
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Elexacaftor/Tezacaftor/Ivacaftor and Neuropsychiatric Symptoms: Nonclinical and Clinical StudiesDOI 10.1101/2025.10.16.25338186
Management of neuropsychiatric symptoms in adults treated with elexacaftor/tezacaftor/ivacaftor.Semantic proximity
Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles.Semantic proximity
Positive and negative impacts of elexacaftor/tezacaftor/ivacaftor: Healthcare providers' observations across US centers.Semantic proximity
Evaluating elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta™) for treatment of patients with non-cystic fibrosis bronchiectasis (NCFB): a clinical study protocolSemantic proximity
Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational StudySemantic proximity
Longitudinal Effects of Elexacaftor/Tezacaftor/Ivacaftor: Multidimensional Assessment of Neuropsychological Side Effects and Physical and Mental Health Outcomes in Adolescents and Adults.Semantic proximity
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.Semantic proximity
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3 Open-Label Extension StudySemantic proximity
Real-world effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis patients with Phe508del -gating and -residual function genotypes.Semantic proximity
Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor.Semantic proximity
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.Semantic proximity
Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation.Semantic proximity
Select a neighboring publication to make it the new centre.